.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Harvard Business School
Cipla
Argus Health
Moodys
Dow
Chinese Patent Office
Queensland Health
Baxter

Generated: September 22, 2017

DrugPatentWatch Database Preview

Synthon Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SYNTHON PHARMS, and what generic alternatives to SYNTHON PHARMS drugs are available?

SYNTHON PHARMS has twelve approved drugs.

There is one US patent protecting SYNTHON PHARMS drugs. There are four tentative approvals on SYNTHON PHARMS drugs.

There are four patent family members on SYNTHON PHARMS drugs in four countries.

Summary for Applicant: Synthon Pharms

Patents:1
Tradenames:10
Ingredients:10
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Synthon Pharms
FLUVOXAMINE MALEATE
fluvoxamine maleate
TABLET;ORAL075899-001Jan 17, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
LEVOCETIRIZINE DIHYDROCHLORIDE
levocetirizine dihydrochloride
TABLET;ORAL090229-001Nov 26, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
RISPERIDONE
risperidone
TABLET;ORAL078187-005Oct 22, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
RISPERIDONE
risperidone
TABLET;ORAL078187-001Oct 22, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
FLUVOXAMINE MALEATE
fluvoxamine maleate
TABLET;ORAL075899-002Jan 17, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
AMLODIPINE BESYLATE
amlodipine besylate
TABLET;ORAL077080-002Jun 27, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
TAMSULOSIN HYDROCHLORIDE
tamsulosin hydrochloride
CAPSULE;ORAL078801-001Apr 27, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
AMLODIPINE BESYLATE
amlodipine besylate
TABLET;ORAL077080-001Jun 27, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
RISPERIDONE
risperidone
TABLET;ORAL078187-003Oct 22, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Synthon Pharms
ZOLPIDEM TARTRATE
zolpidem tartrate
TABLET;ORAL077540-001Apr 23, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for SYNTHON PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

International Patent Family for Synthon Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office1448197► Subscribe
Argentina037565► Subscribe
Australia2002343257► Subscribe
World Intellectual Property Organization (WIPO)03043635► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Synthon Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
07C/043Belgium► SubscribePRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
2015000006Germany► SubscribePRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
00499Netherlands► SubscribePRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
C/GB05/010United Kingdom► SubscribePRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
00625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C/GB96/004United Kingdom► SubscribePRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811
/2005Austria► SubscribePRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Queensland Health
US Army
Cantor Fitzgerald
Medtronic
Boehringer Ingelheim
Deloitte
Teva
Covington
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot